Not actual patient.
Not actual patient.
The safety of PEDMARK was studied in 232 children who received either cisplatin alone or PEDMARK + cisplatin. Only 1 child in each study stopped using PEDMARK due to side effects. The most commonly reported side effect was decreased red blood cells.
Fennec HEARS™ is your single source for both financial and patient support. Call 1-833-7PEDMARK.
Find helpful tools for you or your child.
Please see full Prescribing Information, including Patient Information, for PEDMARK.
PEDMARK is a prescription medicine used to decrease the risk of hearing loss in children 1 month of age and older who are receiving cisplatin for solid tumors (cancer) that have not spread to other parts of the body.
It is not known if PEDMARK is safe and effective when given after cisplatin infusions longer than 6 hours.
It is not known if PEDMARK is safe and effective in children less than 1 month of age. PEDMARK is not recommended in children younger than 1 month of age.